Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Directorate Change

4 Sep 2008 16:35

RNS Number : 7873C
e-Therapeutics plc
04 September 2008
 



e-Therapeutics plc

(the "Company")

Board Change

The Company are pleased to announce the appointment of Brad Hoy as a director of the Company with immediate effect.

Bradley Richard Hoy, aged 45, is appointed as a non-executive director.

He is currently a director of Seven Hills Venture Partners Limited.

In the past five years he has also been a director of the following companies:

Geron Biomed Limited

Xcellsyz Limited

Plethora Solutions Holdings plc

Plethora Solutions Limited

Plethora Therapeutics Limited

Timm Medical Technologies Inc

Plethora Solutions Trustee Company A Limited

Plethora Solutions Trustee Company B Limited

He is not, and has not been, a director or partner of any other company in the last five years.

There is no further information required to be disclosed in accordance with Schedule 2, paragraph (g) of the AIM Rules for Companies

For more information please contact:

John Cordinere-Therapeutics plc

Tel: 0191 233 1317

Katy Mitchell, WH Ireland Limited

Tel: 0113 394 6628

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABUGDCSXGGGIS
Date   Source Headline
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company
16th Feb 202211:47 amRNSHolding(s) in Company
15th Feb 20223:27 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 202210:58 amRNSNew Corporate Website
18th Jan 20224:41 pmRNSHolding(s) in Company
7th Jan 20227:00 amRNSDirector Dealing and Issue of Equity
22nd Nov 20217:00 amRNSSenior Management Update
26th Oct 20211:55 pmRNSDirector Dealing
26th Oct 20217:01 amRNSInterim results for six months ended 31 July 2021
26th Oct 20217:00 amRNSRNAi Platform Characterisation Results
20th Oct 20217:00 amRNSInvestor Presentation
11th Oct 20217:05 amRNSPatent Filing Applications
11th Oct 20217:00 amRNSNotice of Interim Results
24th Sep 20217:00 amRNSCommencement of trading on the OTCQX Best Market
2nd Sep 20214:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSTotal Voting Rights
6th Jul 20217:00 amRNSDirector Dealing and Issue of Equity
2nd Jul 20217:00 amRNSFurther milestone in Galapagos collaboration
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20213:13 pmRNSHolding(s) in Company
21st Jun 20217:00 amRNSHolding(s) in Company
18th Jun 202112:52 pmRNSHolding(s) in Company
17th Jun 20213:44 pmRNSHolding(s) in Company
16th Jun 20211:27 pmRNSResult of AGM
2nd Jun 20217:00 amRNSSenior Management Appointment and Options Grant
21st May 20217:00 amRNSNotice of AGM and Posting of Annual Report
14th May 20217:00 amRNSResults of conditional Fundraise to raise £22.5m
13th May 20214:50 pmRNSRetail Offer
13th May 20214:45 pmRNSProposed Fundraise in excess of £20 million
13th May 20217:00 amRNSFinal Results for the Year Ended 31 January 2021
6th May 20217:00 amRNSNotification of Full Year Results Date
23rd Apr 20217:00 amRNSETX to receive two payments from Galapagos
29th Mar 20217:00 amRNSAppointment of Chief Financial Officer
1st Mar 20217:00 amRNSChange of Adviser
1st Mar 20217:00 amRNSBoard Changes
25th Feb 20213:29 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSe-therapeutics to present at Shares Evening
10th Feb 20214:35 pmRNSHolding(s) in Company
1st Feb 20217:00 amRNSRNA Therapeutics Platform
28th Jan 20214:40 pmRNSSecond Price Monitoring Extn
28th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 202111:24 amRNSHolding(s) in Company
4th Jan 20214:31 pmRNSDirector/PDMR Shareholding
18th Dec 20205:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.